ACTIVE-INGREDIENT OF BARACLUDE 1MG 30TAB
indication of BARACLUDE 1MG 30TAB
Baraclude 1mg Tablet is used in the treatment of HIV infection and chronic hepatitis B virus (HBV) infection. It prevents the multiplication of virus in human cells. This stops the virus from producing new viruses and clears up your infection
of this medicine include headache, nausea, vomiting, stomach pain, fatigue, diarrhea, and rash. These are usually not serious but tell your doctor if they bother you or do not go away. Rarely, some people may experience a skin reaction or liver damage. Your doctor will closely monitor you for these in the initial period of treatment.
Fertility, pregnancy, and lactation
Women of childbearing potential: given that the potential risks to the developing fetus are unknown, women of childbearing potential should use effective contraception.
Pregnancy: there are no adequate data on the use of entecavir in pregnant women. Studies in animals have shown reproductive toxicity at high doses (see section 5.3). The potential risk for humans is unknown. Baraclude should not be used during pregnancy unless clearly necessary. There are no data on the effect of entecavir on the transmission of HBV from mother to newborn infant. Therefore, appropriate interventions should be used to prevent neonatal acquisition of HBV.
it is unknown whether entecavir is excreted in human milk. Available toxicological data in animals have shown excretion of entecavir in milk (for details see section 5.3). A risk to the infants cannot be excluded. Breast-feeding should be discontinued during treatment with Baraclude.
BARACLUDE 1MG 30TAB MANUFACTURED BY Bristol-myers squibb